Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures, and commercialises medicines for the treatment of oncology, autoimmune, cardiovascular, and metabolic, ophthalmology, and other major disease areas, announced on Thursday that it presented for the first time the preclinical data of IAR177 as a poster in ACR Convergence 2026 held in Orlando, Florida.
IAR177 is a bispecific antibody that targets IL-6 and TL1A simultaneously and is designed to overcome the therapeutic ceiling of various rheumatic diseases. Its unique epitope is designed to prevent immune complex formation and reduces immunogenicity risk, while it also blocks IL-6 in its different states.
In-vitro and in-vivo models of rheumatoid arthritis showed a better response than single-target blockade, indicating potential in suboptimal responders and refractory patients. Studies in mice validated this activity, and its pharmacokinetic profile in monkeys supports high-concentration formulation for infrequent subcutaneous dosing.
Founded in 2011, Innovent has launched 20 products. It has one asset under NDA review, six in Phase 3 or pivotal trials and 20 more molecules in early clinical stages. The company has also entered more than 30 strategic partnerships, with an aggregate value of over RMB350bn.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology